Leishmaniasis

Journal of Infection

Volumn 69, Issue S1, 2014, Pages S10-S18

  Pace, David ^a  

^a MATER DEI HOSPITAL   (Malta)

Author keywords

Children; Cutaneous; Leishmaniasis; Muco cutaneous; Sandfly; Visceral

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE ISETHIONATE; STIBOGLUCONATE SODIUM;

ARTICLE; BLISTER; BONE PAIN; CHILL; CLINICAL FEATURE; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DISEASE TRANSMISSION; DRUG MECHANISM; ERYTHEMA; EUROPE; FEVER; GASTROINTESTINAL SYMPTOM; GEOGRAPHY; HEART ARRHYTHMIA; HOST PARASITE INTERACTION; HUMAN; HYPOGLYCEMIA; HYPOKALEMIA; HYPOTENSION; IMMUNE RESPONSE; INJECTION SITE PAIN; LEISHMANIA; LEISHMANIA AETHIOPICA; LEISHMANIA BRAZILIENSIS; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; LEISHMANIA PANAMENSIS; LEISHMANIA PERUVIANA; LEISHMANIA TROPICA; LEISHMANIASIS; LEUKOPENIA; LIFE CYCLE; LIVER TOXICITY; MUCOCUTANEOUS LEISHMANIASIS; NEPHROTOXICITY; NONHUMAN; PAIN; PANCREATITIS; PATHOGENESIS; POST KALA AZAR DERMAL LEISHMANIASIS; PSYCHODIDAE; RASH; SKIN LEISHMANIASIS; SPECIES DISTRIBUTION; TERATOGENICITY; THROMBOCYTOPENIA; VESTIBULOCOCHLEAR NERVE INJURY; VISCERAL LEISHMANIASIS; ANIMAL; CLASSIFICATION; DISEASE CARRIER; LIFE CYCLE STAGE; PARASITOLOGY; PHYSIOLOGY;

ANIMALS; DISEASE VECTORS; HUMANS; LEISHMANIA; LEISHMANIASIS; LIFE CYCLE STAGES;

EID: 84909639482     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2014.07.016     Document Type: Article

References (55)

1. World Health Organization (WHO). Health statistics and health information systems. Global Health Estimates (GHE). Available from: [accessed 09.12.13]. http://www.who.int/healthinfo/global_burden_disease/en/.
2. Ready P.D. Leishmaniasis emergence in Europe. Euro Surveill 2010, 15(10):19505.
3. Field V., Gautret P., Schlagenhauf P., Burchard G.D., Caumes E., Jensenius M., et al. Travel and migration associated infectious diseases morbidity in Europe, 2008. BMC Infect Dis 2010, 10:330. 10.1186/1471-2334-10-330.
4. International Leishmania Network (ILN). Leishmania epidemiology. Available at: [accessed 24.09.13]. http://leish.net/site/.
5. Ready P.D. Biology of phlebotomine sand flies as vectors of disease agents. Annu Rev Entomol 2013, 58:227-250.
6. Bern C., Maguire J.H., Alvar J. Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis 2008, 2(10):e313.
7. Control of the leishmaniases. World Health Organ Tech Rep Ser 2010, 949(xii-xiii):1-186. World Health Organization.
8. Foulet F., Botterel F., Buffet P., Morizot G., Rivollet D., Deniau M., et al. Detection and identification of leishmania species from clinical specimens by using a real-time PCR assay and sequencing of the cytochrome B gene. J Clin Microbiol 2007, 45(7):2110-2115.
9. Killick-Kendrick R. The biology and control of phlebotomine sand flies. Clin Dermatol 1999, 17(3):279-289.
10. Gálvez R., Descalzo M.A., Miró G., Jiménez M.I., Martín O., Dos Santos-Brandao F., et al. Seasonal trends and spatial relations between environmental/meteorological factors and leishmaniosis sand fly vector abundances in Central Spain. Acta Trop 2010, 115(1-2):95-102.
11. Hewitt S., Reyburn H., Ashford R., Rowland M. Anthroponotic cutaneous leishmaniasis in Kabul, Afghanistan: vertical distribution of cases in apartment blocks. Trans R Soc Trop Med Hyg 1998, 92(3):273-274.
12. Jacobson R.L. Leishmania tropica (Kinetoplastida: trypanosomatidae)-a perplexing parasite. Folia Parasitol (Praha) 2003, 50(4):241-250.
13. Bates P.A. Leishmania sand fly interaction: progress and challenges. Curr Opin Microbiol 2008, 11(4):340-344.
14. Hommel M. Visceral leishmaniasis: biology of the parasite. J Infect 1999, 39(2):101-111.
15. Santarém N., Cunha J., Silvestre R., Silva C., Moreira D., Ouellette M., et al. The impact of distinct culture media in Leishmania infantum biology and infectivity. Parasitology 2013, 1-14.
16. World Health Organization (WHO) Leishmaniasis: epidemiology and access to medicines 2012, WHO, Geneva, Switzerland, Available at:, [accessed 11.12.13]. http://www.who.int/leishmaniasis/resources/Leishmaniasis_worldwide_epidemiological_and_drug_access_update.pdf.
17. Okwor I., Uzonna J.E. The immunology of leishmania/HIV co-infection. Immunol Res 2013, 56(1):163-171.
18. World Health Organization (WHO) First WHO report on neglected tropical diseases 2010: working to overcome the global impact of neglected tropical diseases 2010.
19. World Health Organization Regional Office for Europe.The centralized information system for infectious diseases (CISID) Data for southern European countries: Cyprus, France, Greece, Italy, Malta, Portugal, Spain and Turkey 2010, Available at:, [accessed 14.12.13]. http://data.euro.who.int/cisid.
20. Arce A., Estirado A., Ordobas M., Sevilla S., García N., Moratilla L., et al. Re-emergence of leishmaniasis in Spain: community outbreak in Madrid, Spain, 2009 to 2012. Euro Surveill 2013, 18(30):20546.
21. Varani S., Cagarelli R., Melchionda F., Attard L., Salvadori C., Finarelli A.C., et al. Ongoing outbreak of visceral leishmaniasis in Bologna Province, Italy, November 2012 to May 2013. Euro Surveill 2013, 18(29):20530.
22. Zhang W.W., Matlashewski G. Characterization of the A2-A2rel gene cluster in Leishmania donovani: involvement of A2 in visceralization during infection. Mol Microbiol 2001, 39(4):935-948.
23. De Trez C., Magez S., Akira S., Ryffel B., Carlier Y., Muraille E. iNOS-producing inflammatory dendritic cells constitute the major infected cell type during the chronic Leishmania major infection phase of C57BL/6 resistant mice. PLoS Pathog 2009, 5(6):e1000494.
24. Engwerda C.R., Ato M., Kaye P.M. Macrophages, pathology and parasite persistence in experimental visceral leishmaniasis. Trends Parasitol 2004, 20(11):524-530.
25. Alexander J., Brombacher F. T-helper 1/T-helper 2 cells and resistance/susceptibility to leishmania infection: is this paradigm still relevant?. Front Immunol 2012, 3:80.
26. Wei X.Q., Charles I.G., Smith A., Ure J., Feng G.J., Huang F.P., et al. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 1995, 375(6530):408-411.
27. Verma S., Kumar R., Katara G.K., Singh L.C., Negi N.S., Ramesh V., et al. Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasis. PLoS One 2010, 5(4):e10107.
28. Fakiola M., Strange A., Cordell H.J., Miller E.N., Pirinen M., Su Z., et al. Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis. Nat Genet 2013, 45(2):208-213. LeishGEN Consortium, Wellcome Trust Case Control Consortium 2Wellcome Trust Case Control Consortium 2.
29. Desjeux P., Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol 2003, 97(Suppl. 1):3-15.
30. Braga A.S., Toledo Junior A.C., Rabello A. Factors of poor prognosis of visceral leishmaniasis among children under 12 years of age. A retrospective monocentric study in Belo Horizonte, State of Minas Gerais, Brazil, 2001-2005. Rev Soc Bras Med Trop 2013, 46(1):55-59.
31. Ashkan M.M., Rahim K.M. Visceral leishmanisis in paediatrics: a study of 367 cases in southwest Iran. Trop Doct 2008, 38(3):186-188.
32. Grech V., Mizzi J., Mangion M., Vella C. Visceral leishmaniasis in Malta-an 18 year paediatric, population based study. Arch Dis Child 2000, 82(5):381-385.
33. Zijlstra E.E., el-Hassan A.M. Leishmaniasis in Sudan. Visceral leishmaniasis. Trans R Soc Trop Med Hyg 2001, 95(Suppl. 1):S27-S58.
34. Badaro R., Jones T.C., Carvalho E.M., Sampaio D., Reed S.G., Barral A., et al. New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis 1986, 154(6):1003-1011.
35. Collin S., Davidson R., Ritmeijer K., Keus K., Melaku Y., Kipngetich S., et al. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis 2004, 38(5):612-619.
36. Desjeux P., Ghosh R.S., Dhalaria P., Strub-Wourgaft N., Zijlstra E.E. Report of the post kala-azar dermal leishmaniasis (PKDL) consortium meeting, New Delhi, India, 27-29 June 2012. Parasit Vectors 2013, 6:196.
37. Zijlstra E.E., Khalil E.A., Kager P.A., El-Hassan A.M. Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis. Br J Dermatol 2000, 143(1):136-143.
38. Aara N., Khandelwal K., Bumb R.A., Mehta R.D., Ghiya B.C., Jakhar R., et al. Clinco-epidemiologic study of cutaneous leishmaniasis in Bikaner, Rajasthan, India. Am J Trop Med Hyg 2013, 89(1):111-115.
39. Paniz Mondolfi A.E., Duffey G.B., Horton L.E., Tirado M., Reyes Jaimes O., Perez-Alvarez A., et al. Intermediate/borderline disseminated cutaneous leishmaniasis. Int J Dermatol 2013, 52(4):446-455.
40. Blanco V.M., Cossio A., Martinez J.D., Saravia N.G. Clinical and epidemiologic profile of cutaneous leishmaniasis in Colombian children: considerations for local treatment. Am J Trop Med Hyg 2013, 89(2):359-364.
41. Turetz M.L., Machado P.R., Ko A.I., Alves F., Bittencourt A., Almeida R.P., et al. Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil. J Infect Dis 2002, 186(12):1829-1834.
42. Fsadni C., Fsadni P., Piscopo T., Mallia Azzopardi C. Laryngeal leishmaniasis in Malta. J Infect 2007, 54(2):e61-e63.
43. Guerra J.A., Prestes S.R., Silveira H., Coelho L.I., Gama P., Moura A., et al. Mucosal leishmaniasis caused by Leishmania (Viannia) braziliensis and Leishmania (Viannia) guyanensis in the Brazilian Amazon. PLoS Negl Trop Dis 2011, 5(3):e980.
44. Amato V.S., Tuon F.F., Imamura R., Abegão de Camargo R., Duarte M.I., Neto V.A. Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil. J Eur Acad Dermatol Venereol 2009, 23(9):1026-1034.
45. Sundar S., Rai M. Laboratory diagnosis of visceral leishmaniasis. Clin Diagn Lab Immunol 2002, 9(5):951-958.
46. Abeijon C., Campos-Neto A. Potential non-invasive urine-based antigen (protein) detection assay to diagnose active visceral leishmaniasis. PLoS Negl Trop Dis 2013, 7(5):e2161.
47. Neitzke-Abreu H.C., Venazzi M.S., Bernal M.V., Reinhold-Castro K.R., Vagetti F., Mota C.A., et al. Detection of DNA from Leishmania (Viannia): accuracy of polymerase chain reaction for the diagnosis of cutaneous leishmaniasis. PLoS One 2013, 8(7):e62473.
48. Croft S.L., Sundar S., Fairlamb A.H. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006, 19(1):111-126.
49. Palumbo E. Oral miltefosine treatment in children with visceral leishmaniasis: a brief review. Braz J Infect Dis 2008, 12(1):2-4.
50. Sundar S., Chakravarty J. Leishmaniasis: an update of current pharmacotherapy. Expert Opin Pharmacother 2013, 14(1):53-63.
51. Ameen M. Cutaneous leishmaniasis: advances in disease pathogenesis, diagnostics and therapeutics. Clin Exp Dermatol 2010, 35(7):699-705.
52. Singh B., Sundar S. Leishmaniasis: vaccine candidates and perspectives. Vaccine 2012, 30(26):3834-3842.
53. Moosa-Kazemi S.H., Yaghoobi-Ershadir M.R., Akhavan A.A., Abdoli H., Zahraei-Ramazani A.R., Jafari R., et al. Deltamethrin-impregnated bed nets and curtains in an anthroponotic cutaneous leishmaniasis control program in northeastern Iran. Ann Saudi Med 2007, 27(1):6-12.
54. Alexander B., Maroli M. Control of phlebotomine sandflies. Med Vet Entomol 2003, 17(1):1-18.
55. Summary of product characterisitics. CaniLeish, Virbac, France. Available from: [accessed 8.12.13]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/veterinary/002232/WC500104954.pdf.